Merck’s GARDASIL® Receives Expanded Approval for Males in China
Go back to Merck’s GARDASIL® Receives Expanded Approval for Males in China| Merck & Co. (NYSE: MRK) | Delayed: 152.55 +3.56 (2.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.99 | 52 Week High | $65.46 | |||
| Open | $149.12 | 52 Week Low | $47.97 | |||
| Day High | $154.49 | P/E | 103.78 | |||
| Day Low | $148.59 | EPS | $1.47 | |||
| Volume | 15,974,897 | |||||
